Answers are grounded in this paper and cite their sources.
Algal polysaccharides are promising antidiabetic agents due to their structural diversity and ability to modulate multiple metabolic pathways. This review summarizes in vitro and in vivo evidence on polysaccharides from brown, red, and green seaweeds, emphasizing their structural characteristics and mechanisms. They regulate carbohydrate digestion and glucose absorption by inhibiting α-amylase and α-glucosidase and modulating viscosity, substrate accessibility, and intestinal glucose transport. Systemically, they may improve insulin sensitivity and glucose utilization through IRS-1/PI3K/Akt signaling and regulate hepatic glucose and lipid metabolism through AMPK-, PPARγ-, ACC-, SREBP-1C-, and CYP7A1-related pathways. Antioxidant, anti-inflammatory, and gut microbiota-modulating effects may further contribute to metabolic benefits. Their activity is influenced by molecular weight, sulfation, monosaccharide composition, uronic acid content, glycosidic linkages, branching, and conformation. However, structural heterogeneity, inconsistent experimental approaches, limited clinical evidence, and poorly understood gastrointestinal stability remain major challenges requiring integrated structural, mechanistic, clinical, and safety investigations.
No takes yet. Share an insight, caveat, or question.
Zhai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: